Motor neuron disease

Physical Medicine and Rehabilitation Clinics of North America

Volumn 12, Issue 2, 2001, Pages 335-352

  Jackson, C E ^a   Rosenfeld, J ^a  

^a University of Texas Health Science Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; ANTIVIRUS AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXTROMETHORPHAN; GABAPENTIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; LAMOTRIGINE; NEUROTROPHIC FACTOR; NIMODIPINE; PLECONARIL; PREDNISONE; RILUZOLE; SELEGILINE; SOMATOMEDIN C; TALAMPANEL; TOPIRAMATE; UBIDECARENONE; VERAPAMIL; XALIPRODEN;

AMYOTROPHIC LATERAL SCLEROSIS; ANTERIOR HORN CELL; APOPTOSIS; CLINICAL FEATURE; CLINICAL TRIAL; CYTOSKELETON; DEGENERATIVE DISEASE; DIFFERENTIAL DIAGNOSIS; EPIDEMIOLOGICAL DATA; HUMAN; MOTOR NEURON DISEASE; NEUROTRANSMITTER RELEASE; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PYRAMIDAL TRACT; REVIEW; VIRUS INFECTION; WHOLE BODY RADIATION;

EID: 0035039510     PISSN: 10479651     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1047-9651(18)30073-1     Document Type: Review

References (84)

1. Motor neuron disease in textile factory workers
2. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis
3. Genetics of amyotrophic lateral sclerosis: An overview
4. A double-blind study of the effectiveness of cyclosporine in amyotrophic lateral sclerosis
5. Coenzyme Q10 administration and its potential for treatment of neurodegenerative diseases
6. A controlled trial of riluzole in amyotrophic lateral sclerosis
7. A controlled trial of riluzole in amyotrophic lateral sclerosis
8. Detection and cellular localization of enterovirus RNA sequences in spinal cord of patients with ALS
9. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis
10. Study of epidemiological and etiological factors of amyotrophic lateral sclerosis in the province of Florence, Italy
11. Factors influencing the use of riluzole by ALS patients
12. Oxidative stress as a mediator of apoptosis
13. De la sclerose laterale amytrophique
14. Oxidative stress and motor neuron disease
15. Progressive neuronopathy in transgenic mice expressing the human neurofilament heavy gene: A mouse model of amyotrophic lateral sclerosis
16. Physical trauma and family history of neurodegenerative diseases in amyotrophic lateral sclerosis: A population-based case-control study
17. Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation
18. Duration of amyotrophic lateral sclerosis is age dependent
19. Anti-glutamate therapy in amyotrophic lateral Sclerosis: A trial using lamotrigine
20. Antecedent events in amyotrophic lateral sclerosis
21. Protective effects of SR 57746A in central and peripheral models of neurodegenerative disorders in rodents and primates
22. Inhibition of ICE slows ALS in mice
23. Trauma and amyotrophic lateral sclerosis: A report of 78 patients
24. Epidemiological study of amyotrophic lateral sclerosis in Sardinia, Italy
25. Motor neuron disease in the province of Ferrara, Italy, in 1964-1982
26. A clinical trial of dextromethorphan in amyotrophic lateral sclerosis
27. Motor neuron disease and heavy manual labor: An epidemiological survey of Varmland County, Sweden
28. The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies
29. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis
30. Motor neuron disease: A disorder secondary to solvent exposure?
31. Fine structural study of neurofibrillary changes in a family with amyotrophic lateral sclerosis
32. Antagonism by riluzole of entry of calcium evoked by NMDA and veratridine in rate cultured granule cells: Evidence for a dual mechanism of action
33. Expression of human copper/zinc-superoxide dismutase inhibits the death of rat sympathetic neurons caused by withdrawal of nerve growth factor
34. Double-blind cross over trial with deprenyl in amyotrophic lateral sclerosis
35. A basic biological phenomenon with wide-ranging implications in tissue kinetics
36. Bipap improves survival and rate of pulmonary function decline in patients with ALS
37. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis
38. Dose-ranging study of riluzole in amyotrophic lateral sclerosis/Riluzole Study Group II
39. Effect of recombinant human insulin-like growth factor-I on progression of ALS: A placebo-controlled study
40. Cytoskeletal pathology in motor neuron diseases
41. Nerve growth factor
42. Rescue of adult mouse motoneurons from injury-induced cell death by glial cell line-derived neurotrophic factor
43. Aberrant RNA processing in a neurodegenerative disease: The cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis
44. Neurotrophic growth factors and neurodegenerative diseases: Therapeutic potential of the neurotrophins and ciliary neurotrophic factor
45. Trophic protection of motor neurons: Clinical potential in motor neuron diseases
46. Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis
47. Apoptosis, oncosis, and necrosis: An overview of cell death
48. The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area of CA1
49. An open-randomized clinical trial of selegiline in amyotrophic lateral sclerosis
50. An open-randomized clinical trial of selegiline in amyotrophic lateral sclerosis
51. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis
52. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis
53. A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis
54. Controlled trial of nimodipine in amyotrophic lateral sclerosis
55. A clinical trial of verapamil in amyotrophic lateral sclerosis
56. Clinical limits of amyotrophic lateral sclerosis
57. Patient resistance and prognosis in amyotrophic lateral sclerosis
58. Onset, natural history and outcome in idiopathic adult motor neuron disease
59. An assessment of the efficacy and safety of LY300164 in patients with amyotrophic lateral sclerosis
60. Evidence for nerve growth factor-potentiating activities of the nonpeptidic compound SR 57746A in PC12 cells
61. Antecedent events in amyotrophic lateral sclerosis: Do they influence clinical onset and progression?
62. Antecedent trauma and amyotrophic lateral sclerosis in young adult men
63. Trauma, axonal injury, and amyotrophic lateral sclerosis: A clinical correlate of a neuropharmacologic model
64. The natural history of amyotrophic lateral sclerosis
65. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole
66. Studies on epidemiological, clinical, and etiological aspects of ALS disease in Sardinia, Southern Italy
67. Mutations in Cu/Zn superoxide dismutase are associated with familial amyotrophic lateral sclerosis
68. SR 57746A attenuates cytostatic drug-induced reduction of neurite outgrowth In co-cultures of rat dorsal root ganglia and Schwann cells
69. Cytotoxicity of immunoglobulins from amyotrophic lateral sclerosis patients on a hybrid motoneuron cell line
70. Autoimmunity and ALS
71. Treatment of ALS with high dose pulse cyclophosphamide
72. Amyotrophic lateral sclerosis and occupational history. A pilot case-control study
73. Immunosuppressive treatment of motor neuron syndromes: Attempts to distinguish a treatable disorder
74. A controlled trial of amino acid therapy in amyotrophic lateral sclerosis: I. Clinical, functional, and maximum isometric torque data
75. A controlled trial of recombinant methionyl human BDNF in ALS: (Phase III)
76. Branched-chain amino acids and amyotrophic lateral sclerosis: A treatment failure?
77. Oxidative stress, mutant SOD1, and neurofilament pathology in transgenic mouse models of human motor neuron disease
78. Transgenic mice carrying a human mutant superoxide dismutase transgene develop neuronal cytoskeletal pathology resembling human amyotrophic lateral sclerosis lesions
79. Subacute, reversible motor neuron disease
80. Amyotrophic lateral sclerosis: Effect of serum on anterior horn cells in tissue culture
81. Increasing neurofilament subunit NF-M expression reduces axonal NF-H, inhibits radial growth, and results in neurofilamentous accumulation in motor neurons
82. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis
83. The biological responses of axotomized adult motoneurons to brain-derived neurotrophic factor
84. Apoptosis related antigen, Le(Y) and nick-end labeling are positive in spinal motor neurons in amyotrophic lateral sclerosis